Theralink (THER) 10-Q2023 Q2 Quarterly report

Filed: 15 May 23, 4:12pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	Coll freshman Bad

New words: abundance, accommodating, accuracy, advantage, aid, answer, approach, Array, Asia, Attain, biopharma, biopsy, bladder, blood, body, broaden, built, Canada, categorized, category, CDx, cell, central, client, colorectal, companion, concurrently, correlation, Deepen, deliver, demonstrate, demonstrated, deruxtecan, diabetic, discovery, downstream, easily, efficacy, elucidating, empower, endpoint, enroll, epidermal, essential, essentially, Europe, eventually, evolving, experimental, exploit, explore, exposed, face, faced, facilitate, facing, fatty, FDA, feedback, foot, gastrointestinal, genomic, guide, guiding, gynecological, hair, hallmark, hand, harsh, healthcare, healthy, hesitance, high, histologic, human, ideal, identification, immunohistochemistry, impractical, infrastructure, investigate, investigational, launch, LDT, leadership, lifetime, low, main, mapping, meaningful, Mergenthaler, metastasize, missed, mononuclear, narrowing, network, nonalcoholic, oncologist, opportunity, paired, panel, peripheral, Phase, phosphorylated, physiologic, practice, preclinical, predecessor, predict, predicted, predicting, prediction, predictive, predictor, prepayment, procedure, prognostic, progression, proteomic, radiographic, receptor, repurposed, requisite, resistance, reveal, rival, RNA, role, run, satisfactory, save, sequencing, signaling, solid, strip, structure, suggest, superior, surrogate, system, tailored, threshold, tiered, tissue, tool, toolset, toxic, Traditional, transcriptomic, trastuzumab, Treasurer, type, ulcer, unmet, Vanderbilt, visibility

Removed: Center, CMS, commercialize, community, elevated, Emanuel, Espina, exciting, focused, government, independence, Lance, Liotta, Medicaid, meeting, NASDAQ, noted, objective, ongoing, originally, pandemic, partner, Petricoin, phosphoproteomic, PHS, pioneering, removal, renew, resignation, sit, subsequently, successor, validate, Virginia, voted

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

THER similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Theralink Technologies, Inc. (the “Company”) for the quarter ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Mick Ruxin, MD, Chief Executive Officer of the Company and I, Andrew Kucharchuk, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

	1.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	2.	The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

	THERALINK TECHNOLOGIES, INC.

Date: May 15, 2023	By:	/s/ Mick Ruxin, MD
		Mick Ruxin, MD
		Chief Executive Officer (Principal Executive Officer)

Date: May 15, 2023	By:	/s/ Andrew Kucharchuk
		Andrew Kucharchuk
		Chief Financial Officer (Principal Financial Officer)

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.